Latest News and Press Releases

SAN MATEO, Calif. and SINGAPORE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative...

Head-to-head study between eblasakimab and dupilumab in skin biopsies from atopic dermatitis (AD) patients confirm eblasakimab’s differentiated effects of targeting IL-13R vs IL-4RUsing an established...

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, met the primary endpoint across three dosing arms; the study established...

Discussion featuring KOLs Dr Jonathan Silverberg, Dr April W. Armstrong, and a leading CRO will explore “The Changing Face of Atopic Dermatitis: How the Clinical Trial and Treatment Landscape Has...

ASLAN management will present emerging data from the TREK-AD study and new market research data on the AD treatment landscape from patient and prescriber surveysRegister here to attend the webinar...

Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate eblasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a...

SAN MATEO, Calif. and SINGAPORE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established...

Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks,...